StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Keros Therapeutics

Keros Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Keros Therapeutics figures

See a number that looks wrong?